Lilly Cares Foundation Patient Assistance Program

PO Box 13185 La Jolla, CA 92039 Phone: 1-800-545-6962 Fax: 1-844-431-6650 www.lillycares.com



Lilly Cares Prescription FAX Form Emgality®

Patient Name:	Date of Birth:		
Address:	Telephone Number:		
RX: I authorize Lilly Cares to act on my behalf for the purpose of transmitting this prescription to the appropriate pharmacy. Emgality® (galcanezumab-gnlm) injection, for subcutaneous use Please indicate patient's treatment plan by completing one of the below options:			
		Emgality® is indicated for the treatment of episodic cluster headache Injection Device: □ prefilled syringe (100 mg/mL) Monthly Dose: □ 300 mg subcutaneous at the start of a cluster cycland then every month as needed until the end of	
		Quantity to be dispensed:	
		Your state may require that prescriptions follow certain content requireme abiding by laws applicable to prescriptions and authorized prescribers in the behalf for the limited purposes of transmitting this order for prescription metals.	the states in which you are prescribing. I authorize Lilly Cares to act on my
Signature: Dispense as written	Substitution/brand exchange permitted		
Supervising Physician Signature and Date (where required):	d computer-generated signatures will not be accepted.		
	Phone:		
Prescriber Office/Clinic Name and Shipping Address (No PO Box):			

IMPORTANT: This information is intended for the use of the person or entity to which it is addressed and may contain information that is confidential, the disclosure of which is governed by applicable law. If the reader of this information is not the intended recipient, or the authorized agent or individual responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this information is STRICTLY PROHIBITED. If you received this document in error, please notify us immediately and destroy the related document.

PP-AP-US-0357 06/2019 © Lilly USA, LLC 2019. All rights reserved. Emgality® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.